Bristol Myers' treatment succeeds in late-stage bowel disease study
June 02, 2020 at 06:59 AM EDT
U.S. drugmaker Bristol Myers Squibb Co said on Tuesday its treatment Zeposia, which it gained through its $74 billion buyout of Celgene last year, met the main goals of a late-stage study testing it in patients with an inflammatory bowel disease.
